Procter & Gamble has inked a development deal with Aryx Therapeutics for Aryx's gastrointestinal disorder drug. Aryx gets $25 million up front for the licensing deal on ATI-7505, with total payments for a successful commercial launch adding up to $435 million. Aryx retains an option to co-develop and promote the therapy.
- here's the AP report [1] on the licensing deal
Links:
[1] http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20060711&ID=5859188